LXRX - Lexicon Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
The Woodlands,
United States
Type: Equity
LXRX price evolution
LXRX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $35.62 | $96.49 | $22.46 | |
| Short term investments | $274.35 | $259.1 | $147.56 | |
| Net receivables | $2.9 | $2.62 | $1.53 | $1.01 |
| Inventory | $0.64 | $0.58 | $0.51 | $0.38 |
| Total current assets | $268.61 | $320.84 | $364.65 | $176.55 |
| Long term investments | ||||
| Property, plant & equipment | $7.15 | $7.14 | $7.2 | $7.51 |
| Goodwill & intangible assets | $44.54 | $44.54 | $44.54 | |
| Total noncurrent assets | $52.51 | $52.57 | $52.88 | |
| Total investments | $274.35 | $259.1 | $147.56 | |
| Total assets | $321.12 | $373.36 | $417.22 | $229.43 |
| Current liabilities | ||||
| Accounts payable | $14.2 | $12.22 | $8.07 | $14.39 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $36.05 | $27.88 | $23.4 | $31.55 |
| Long term debt | $99.89 | $99.5 | $104.95 | $104.77 |
| Total noncurrent liabilities | $105.5 | $104.95 | $104.77 | |
| Total debt | $99.5 | $104.95 | $104.77 | |
| Total liabilities | $142.61 | $133.38 | $128.35 | $136.32 |
| Shareholders' equity | ||||
| Retained earnings | -$1933.48 | -$1868.66 | -$1815.24 | -$1766.84 |
| Other shareholder equity | $0.35 | -$0.19 | -$0.05 | $0.03 |
| Total shareholder equity | $239.98 | $288.87 | $93.11 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.46 | $46.34 | $64.06 | $126.26 |
| Short term investments | $147.56 | $92.01 | $22.68 | $26.01 |
| Net receivables | $1.01 | $0.03 | $0.01 | $0.4 |
| Inventory | $0.38 | |||
| Total current assets | $176.55 | $140.87 | $88.92 | $157.72 |
| Long term investments | ||||
| Property, plant & equipment | $7.51 | $4.37 | $1.18 | $0.29 |
| Goodwill & intangible assets | $44.54 | $44.54 | $44.54 | $44.54 |
| Total noncurrent assets | $52.88 | $53.43 | $47.99 | $46.07 |
| Total investments | $147.56 | $92.01 | $22.68 | $26.01 |
| Total assets | $229.43 | $194.3 | $136.91 | $203.79 |
| Current liabilities | ||||
| Accounts payable | $14.39 | $10.39 | $9.15 | $5.47 |
| Deferred revenue | ||||
| Short long term debt | $11.65 | |||
| Total current liabilities | $31.55 | $23.17 | $22.12 | $46.81 |
| Long term debt | $104.77 | $48.58 | ||
| Total noncurrent liabilities | $104.77 | $54 | $1.19 | $0.61 |
| Total debt | $104.77 | $54 | $11.65 | |
| Total liabilities | $136.32 | $77.17 | $23.31 | $47.42 |
| Shareholders' equity | ||||
| Retained earnings | -$1766.84 | -$1589.72 | -$1487.78 | -$1400.02 |
| Other shareholder equity | $0.03 | -$0.43 | -$0.01 | -$0.01 |
| Total shareholder equity | $93.11 | $117.12 | $113.59 | $156.37 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.75 | $1.65 | $1.13 | $0.7 |
| Cost of revenue | $0.17 | $0.03 | $0.07 | |
| Gross Profit | $1.68 | $1.48 | $1.1 | $0.63 |
| Operating activities | ||||
| Research & development | $17.64 | $14.37 | $14.76 | |
| Selling, general & administrative | $39.19 | $32.06 | $32.61 | |
| Total operating expenses | $65.37 | $56.84 | $46.43 | $47.37 |
| Operating income | -$55.35 | -$45.33 | -$46.74 | |
| Income from continuing operations | ||||
| EBIT | -$51.22 | -$43.45 | -$44.34 | |
| Income tax expense | ||||
| Interest expense | -$4.56 | $2.21 | $4.95 | $5.42 |
| Net income | ||||
| Net income | -$64.81 | -$53.43 | -$48.4 | -$49.76 |
| Income (for common shares) | -$53.43 | -$48.4 | -$49.76 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.2 | $0.14 | $0.3 | $24 |
| Cost of revenue | $0.09 | $1.93 | ||
| Gross Profit | $1.12 | $0.14 | $0.3 | $22.07 |
| Operating activities | ||||
| Research & development | $58.89 | $52.82 | $55.05 | $153.62 |
| Selling, general & administrative | $113.98 | $48.08 | $32.34 | $47.23 |
| Total operating expenses | $172.87 | $100.9 | $87.39 | $69.87 |
| Operating income | -$171.75 | -$100.76 | -$87.09 | -$47.8 |
| Income from continuing operations | ||||
| EBIT | -$164.02 | -$99.16 | -$86.96 | -$44.03 |
| Income tax expense | ||||
| Interest expense | $13.1 | $2.78 | $0.8 | $14.54 |
| Net income | ||||
| Net income | -$177.12 | -$101.94 | -$87.76 | -$58.57 |
| Income (for common shares) | -$177.12 | -$101.94 | -$87.76 | -$58.57 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$53.43 | -$48.4 | -$49.76 | |
| Operating activities | ||||
| Depreciation | $0.14 | $0.14 | $0.15 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.86 | $4.3 | $3.21 | |
| Total cash flows from operations | -$48.54 | -$55.13 | -$50.55 | |
| Investing activities | ||||
| Capital expenditures | -$0.25 | |||
| Investments | -$12.07 | -$110.22 | $51.9 | |
| Total cash flows from investing | -$69.08 | -$12.32 | -$110.22 | $51.9 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | -$1.64 | ||
| Net borrowings | -$0 | |||
| Total cash flows from financing | $238.45 | -$0.01 | $239.38 | -$0 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $12.09 | -$60.88 | $74.03 | $1.35 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$177.12 | -$101.94 | -$87.76 | -$58.57 |
| Operating activities | ||||
| Depreciation | $0.55 | $0.43 | $0.29 | $2.93 |
| Business acquisitions & disposals | $160.38 | |||
| Stock-based compensation | $14.34 | $11.52 | $10.58 | $13.27 |
| Total cash flows from operations | -$161.9 | -$88.85 | -$87.02 | -$142.97 |
| Investing activities | ||||
| Capital expenditures | -$0.47 | -$1.33 | -$1.22 | $10.93 |
| Investments | -$49.47 | -$69.75 | $3.33 | $209.44 |
| Total cash flows from investing | -$49.94 | -$71.08 | $2.11 | $380.76 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $138 | $93.34 | $34.41 | $68.94 |
| Net borrowings | $49.96 | $48.87 | -$11.7 | -$216.58 |
| Total cash flows from financing | $187.96 | $142.21 | $22.71 | -$147.64 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$23.88 | -$17.72 | -$62.2 | $90.15 |
News
Fundamentals
| Market cap | $314.50M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 361.49M |
| Revenue | $5.23M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$216.39M |
| Revenue Q/Q | 980.25% |
| Revenue Y/Y | 884.75% |
| P/E ratio | -1.45 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 60.15 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.60 |
|---|---|
| ROA | -64.54% |
| ROE | N/A |
| Debt/Equity | 1.46 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.45 |
| Quick ratio | 7.43 |